A
Alba Rodriguez Meira
Researcher at University of Oxford
Publications - 6
Citations - 139
Alba Rodriguez Meira is an academic researcher from University of Oxford. The author has contributed to research in topics: Haematopoiesis & Progenitor cell. The author has an hindex of 3, co-authored 6 publications receiving 96 citations. Previous affiliations of Alba Rodriguez Meira include Medical Research Council & Imperial College London.
Papers
More filters
Journal ArticleDOI
Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion
Van T. M. Nguyen,Iros Barozzi,Monica Faronato,Ylenia Lombardo,Jennifer H. Steel,Naina Patel,Philippa D. Darbre,Leandro Castellano,Balázs Győrffy,Laura Woodley,Alba Rodriguez Meira,Darren K. Patten,Valentina Vircillo,Manikandan Periyasamy,Simak Ali,Gianmaria Frigè,Saverio Minucci,R. Charles Coombes,Luca Magnani +18 more
TL;DR: It is demonstrated that resistance emerges via drug-specific epigenetic reprogramming in AI-resistant cells and Epigenomic-led stratification can predict resistance to AI in a subset of ERα-positive patients.
Journal ArticleDOI
Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development.
Anindita Roy,Anindita Roy,Anindita Roy,Guanlin Wang,Deena Iskander,Sorcha O’Byrne,Natalina Elliott,Jennifer O'Sullivan,Gemma Buck,Gemma Buck,Elisabeth F. Heuston,Wei Xiong Wen,Alba Rodriguez Meira,Peng Hua,Anastasios Karadimitris,Adam J. Mead,Adam J. Mead,David M. Bodine,Irene Roberts,Irene Roberts,Irene Roberts,Bethan Psaila,Bethan Psaila,Supat Thongjuea,Supat Thongjuea +24 more
TL;DR: In this article, the authors compare 57,489 HSPCs from 5 different tissues spanning four developmental stages through the human lifetime, and demonstrate the utility of this dataset for understanding aberrant hematopoiesis through comparison to two cancers that present at distinct time points in postnatal life.
Posted ContentDOI
Single-cell analyses reveal aberrant pathways for megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets
Bethan Psaila,Guanlin Wang,Guanlin Wang,Alba Rodriguez Meira,Alba Rodriguez Meira,Rong Li,Rong Li,Elisabeth F. Heuston,Lauren Murphy,Lauren Murphy,Daniel Yee,Daniel Yee,Ian S. Hitchcock,Nikolaos Sousos,Nikolaos Sousos,Jennifer O'Sullivan,Jennifer O'Sullivan,Stacie M. Anderson,Yotis A. Senis,Olga K. Weinberg,Monica L. Calicchio,Deena Iskander,Daniel Royston,Dragana Milojkovic,Irene Roberts,David M. Bodine,Supat Thongjuea,Adam J. Mead,Adam J. Mead +28 more
TL;DR: The immunoglobulin receptor G6B is validated as a promising JAK2-mutant clone-specific antigen warranting further development as an immunotherapy target and the power of single-cell multi-omics to discover tumor-specific therapeutic targets and mediators of tissue fibrosis is illustrated.
Posted ContentDOI
SREBP1 drives KRT80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ERα breast cancer
Luca Magnani,Ylenia Perone,Aaron J. Farrugia,Alba Rodriguez Meira,Balazs Gyorffy,Balazs Gyorffy,Charlotte Ion,Andrea Uggetti,Darren K. Patten,Antonios Chronopoulos,Monica Faronato,Sami Shousha,Jenny Steel,Claire Davies,Naina Patel,Armando del Río Hernández,R. C. Coombes,Giancarlo Pruneri,Adrian Lim,Fernando Calvo +19 more
TL;DR: The data uncover an unpredicted and potentially targetable direct link between epigenetic and cytoskeletal reprogramming promoting cell invasion in response to chronic AI treatment.
Posted ContentDOI
Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia
E Louka,Benjamin J. Povinelli,Alba Rodriguez Meira,Gemma Buck,Neil Ashley,Angela Hamblin,Christopher A.G. Booth,Nikolaos Sousos,Anindita Roy,Natalina Elliott,Deena Iskander,Josu de la Fuente,Nicholas Fordham,Sorcha O’Byrne,Sarah Inglott,Anupama Rao,Irene Roberts,Irene Roberts,Adam J. Mead,Adam J. Mead +19 more
TL;DR: RNA-sequencing of JMML-LSCs reveals upregulation of stem cell and fetal genes (HLF, MEIS1, CNN3, VNN2, HMGA2) and candidate therapeutic targets/biomarkers paving the way for LSC-directed disease monitoring and therapy in this disease.